DeuterOncology NV
Latest round
- Series A
Last raised
- Jan 2023
Total raised
- $5.8M
Investors
- 3
About DeuterOncology NV
Based in Gell, Belgium, and founded in 2020, DeuterOncology NV develops DO-2, a novel MET and RAS pathway inhibitor. The company was founded by Dr. Timothy Perera. The company is focusing on the development of a dual MET and RAS pathway inhibitor for targeted cancer therapies. The company's solution, which overcomes resistance to MET inhibitors, can be used in monotherapy and combination therapy setting for cancer patients.
Who invested in DeuterOncology NV
3 investors across 1 round
See all investors in DeuterOncology NV
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jan 2, 2023
Amount
$5.8M
Investors
Questions about DeuterOncology NV
Who invested in DeuterOncology NV?
DeuterOncology NV has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has DeuterOncology NV raised?
DeuterOncology NV has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did DeuterOncology NV last raise money?
DeuterOncology NV's most recent round on record is a Series A, in Jan 2023.
What does DeuterOncology NV do?
Based in Gell, Belgium, and founded in 2020, DeuterOncology NV develops DO-2, a novel MET and RAS pathway inhibitor.
Where is DeuterOncology NV headquartered?
DeuterOncology NV is headquartered in Liege, Belgium.
Which VCs invest in companies like DeuterOncology NV?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at DeuterOncology NV's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like DeuterOncology NV? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.